Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study.

Abstract

The aim of this study was to determine the efficacy and safety of a weekly dose of leflunomide (50mg/week) in early rheumatoid arthritis patients with mild or moderate disease activity. The patients of early rheumatoid arthritis (ERA) with mild or moderate disease activity were randomly selected for inclusion in this study and were assigned to either the treatment group (leflunomide 50mg/week, LEF50) or the control group (leflunomide 10mg/day, LEF10). All patients were treated for 24weeks. Clinical efficacy was assessed using the disease activity score in 28 joints (DAS28) - erythrocyte sedimentation rate (ESR) and European League Against Rheumatism (EULAR) response. A Chi-squared test, Fisher's exact-test and paired t-tests were used to analyze the data. A total of 244 patients who met the inclusion criteria and received at least one medicine dose were analyzed. At the baseline, the DAS28 (ESR) of the ERA patients were 4.41±0.69 in LEF 50 group and 4.52±0.64 in LEF 10 group, respectively. At week 24, the DAS28 (ESR) in two groups ( 2.94±1.10 and 3.02±1.14 ) were significant decreased compare with the baseline, respectively (P<0.01). There was no significant difference in DAS28 (ESR) between the LEF50 and LEF10 groups at week 24. (P>0.05). At weeks 8, 12 and 24, the EULAR response (good responses+moderate responses) were 47.6%, 58.7% and 59.5%, in the LEF50 group and 43.2%, 49.1% and 53.4% in the LEF10 group, respectively. There was no significant different of EULAR response rates in the two groups at week 8, 12, and 24, respectively (P>0.05). There was no serious adverse events during the study. A weekly dose of 50mg leflunomide showed similar benefits to a daily dose of 10mg leflunomide for the treatment of mild-to-moderate early rheumatoid arthritis.